Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fortress Biotech Inc (FBIO)

Fortress Biotech Inc (FBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 101,805
  • Shares Outstanding, K 31,038
  • Annual Sales, $ 57,680 K
  • Annual Income, $ -46,000 K
  • EBIT $ -83 M
  • EBITDA $ -74 M
  • 60-Month Beta 1.42
  • Price/Sales 1.55
  • Price/Cash Flow N/A
  • Price/Book 1.78

Options Overview Details

View History
  • Implied Volatility 103.81% (-46.61%)
  • Historical Volatility 82.83%
  • IV Percentile 9%
  • IV Rank 4.02%
  • IV High 1,000.47% on 11/10/25
  • IV Low 66.25% on 11/20/25
  • Expected Move (DTE 1) 0.84 (24.75%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 423
  • Volume Avg (30-Day) 1,861
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 33,627
  • Open Int (30-Day) 27,267
  • Expected Range 2.56 to 4.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.42
  • Number of Estimates 1
  • High Estimate 0.42
  • Low Estimate 0.42
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +261.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.21 +5.30%
on 12/16/25
4.53 -25.39%
on 01/09/26
+0.06 (+1.81%)
since 12/15/25
3-Month
2.38 +41.72%
on 11/04/25
4.53 -25.39%
on 01/09/26
+0.56 (+19.86%)
since 10/15/25
52-Week
1.33 +154.14%
on 04/09/25
4.53 -25.39%
on 01/09/26
+1.50 (+79.79%)
since 01/15/25

Most Recent Stories

More News
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million...

FBIO : 3.53 (+7.62%)
FBIOP : 12.40 (+0.49%)
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the...

FBIO : 3.53 (+7.62%)
FBIOP : 12.40 (+0.49%)
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on...

FBIO : 3.53 (+7.62%)
DERM : 8.20 (+4.59%)
Fortress Biotech: Q3 Earnings Snapshot

Fortress Biotech: Q3 Earnings Snapshot

FBIO : 3.53 (+7.62%)
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights 

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received...

FBIO : 3.53 (+7.62%)
FBIOP : 12.40 (+0.49%)
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold...

FBIO : 3.53 (+7.62%)
DERM : 8.20 (+4.59%)
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

FBIO : 3.53 (+7.62%)
ATXI : 0.6815 (+9.28%)
AXSM : 176.50 (-0.29%)
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused...

FBIO : 3.53 (+7.62%)
DERM : 8.20 (+4.59%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortress Biotech Inc. ("Fortress" or the "Company") (NASDAQ: FBIO). Such investors are advised...

FBIO : 3.53 (+7.62%)
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions...

FBIO : 3.53 (+7.62%)
DERM : 8.20 (+4.59%)

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Key Turning Points

3rd Resistance Point 4.27
2nd Resistance Point 4.06
1st Resistance Point 3.67
Last Price 3.53
1st Support Level 3.07
2nd Support Level 2.86
3rd Support Level 2.47

See More

52-Week High 4.53
Last Price 3.53
Fibonacci 61.8% 3.31
Fibonacci 50% 2.93
Fibonacci 38.2% 2.55
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar